PanGen Biotech Valuation
222110 Stock | KRW 6,000 290.00 4.61% |
At this time, the company appears to be fairly valued. PanGen Biotech holds a recent Real Value of W5766.25 per share. The prevailing price of the company is W6000.0. Our model determines the value of PanGen Biotech from analyzing the company fundamentals such as Return On Equity of -24.89, shares owned by institutions of 2.47 %, and Operating Margin of (0.82) % as well as examining its technical indicators and probability of bankruptcy.
Fairly Valued
Today
Please note that PanGen Biotech's price fluctuation is very steady at this time. Calculation of the real value of PanGen Biotech is based on 3 months time horizon. Increasing PanGen Biotech's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since PanGen Biotech is currently traded on the exchange, buyers and sellers on that exchange determine the market value of PanGen Stock. However, PanGen Biotech's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. Historical | Market 6000.0 | Real 5766.25 | Hype 6000.0 | Naive 5453.58 |
The real value of PanGen Stock, also known as its intrinsic value, is the underlying worth of PanGen Biotech Company, which is reflected in its stock price. It is based on PanGen Biotech's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of PanGen Biotech's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of PanGen Biotech helps investors to forecast how PanGen stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of PanGen Biotech more accurately as focusing exclusively on PanGen Biotech's fundamentals will not take into account other important factors: PanGen Biotech Total Value Analysis
PanGen Biotech is presently forecasted to have takeover price of 90.89 B with market capitalization of 59.88 B, debt of 5.49 M, and cash on hands of 8.9 B. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the PanGen Biotech fundamentals before making investing decisions based on enterprise value of the companyTakeover Price | Market Cap | Debt Obligations | Cash |
90.89 B | 59.88 B | 5.49 M | 8.9 B |
PanGen Biotech Investor Information
About 33.0% of the company shares are owned by insiders or employees . The company had not issued any dividends in recent years. Based on the key indicators obtained from PanGen Biotech's historical financial statements, PanGen Biotech is not in a good financial situation at the moment. It has a very high risk of going through financial straits in December.PanGen Biotech Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. PanGen Biotech has an asset utilization ratio of 18.34 percent. This suggests that the Company is making W0.18 for each dollar of assets. An increasing asset utilization means that PanGen Biotech is more efficient with each dollar of assets it utilizes for everyday operations.PanGen Biotech Ownership Allocation
The market capitalization of PanGen Biotech is W59.88 Billion. PanGen Biotech has significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Note, that even with negative profits, if the true value of the company is larger than the current market value, you may still be able to generate positive returns on investment in this company.PanGen Biotech Profitability Analysis
The company reported the revenue of 7.94 B. Net Loss for the year was (3.31 B) with profit before overhead, payroll, taxes, and interest of 1.35 B.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates PanGen Biotech's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in PanGen Biotech and how it compares across the competition.
About PanGen Biotech Valuation
The stock valuation mechanism determines PanGen Biotech's current worth on a weekly basis. Our valuation model uses a comparative analysis of PanGen Biotech. We calculate exposure to PanGen Biotech's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of PanGen Biotech's related companies.PanGen Biotech Inc. operates as a specialized biologics company in South Korea. The company was founded in 1999 and is based in Suwon, South Korea. PanGen is traded on Korean Securities Dealers Automated Quotations in South Korea.
8 Steps to conduct PanGen Biotech's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates PanGen Biotech's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct PanGen Biotech's valuation analysis, follow these 8 steps:- Gather financial information: Obtain PanGen Biotech's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine PanGen Biotech's revenue streams: Identify PanGen Biotech's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research PanGen Biotech's industry and market trends, including the size of the market, growth rate, and competition.
- Establish PanGen Biotech's growth potential: Evaluate PanGen Biotech's management, business model, and growth potential.
- Determine PanGen Biotech's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate PanGen Biotech's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Complementary Tools for PanGen Stock analysis
When running PanGen Biotech's price analysis, check to measure PanGen Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PanGen Biotech is operating at the current time. Most of PanGen Biotech's value examination focuses on studying past and present price action to predict the probability of PanGen Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PanGen Biotech's price. Additionally, you may evaluate how the addition of PanGen Biotech to your portfolios can decrease your overall portfolio volatility.
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Content Syndication Quickly integrate customizable finance content to your own investment portal | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
Stocks Directory Find actively traded stocks across global markets | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules |